Skip to Content
  • Previous Rank72
  • Revenue 3 Yr Annual Growth Rate27%
  • Revenue 3 Yr Growth Rank53
  • EPS 3 Yr Annual Growth Rate42%
  • EPS 3 Yr Growth Rank44
  • Total Return 3 Yr Annual Rate4%
  • Total Return 3 Yr Rank
    94

Multiple sclerosis drug Tecfidera continues to boost revenue for this biotech–a stalwart of this list, appearing for the seventh time.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Location
Cambridge, Mass.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak2
Years on List7
CEO
George Scangos
Websitehttp://www.biogen.com
Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.

Revenue, Net Income

Revenue Past Four Quarters ($M)$10,936
Net Income Past Four Quarters ($M)$3,695

Growth Rates and Ranks

Revenue 3 Yr Growth Rank53
EPS 3 Yr Annual Growth Rate42%
EPS 3 Yr Growth Rank44
Total Return 3 Yr Annual Rate4%
Total Return 3 Yr Rank
94